Hyperfine (NASDAQ:HYPR) Inc (NASDAQ: HYPR) is a medical technology company specializing in the development and commercialization of portable magnetic resonance imaging (MRI) systems. Its flagship product, the Swoop® Portable MR Imaging System, employs low-field magnet technology to deliver point-of-care neuroimaging in settings where traditional MRI scanners are impractical. By eliminating the need for specialized infrastructure such as shielded rooms and heavy gantries, Hyperfine aims to broaden access to critical imaging services in emergency departments, intensive care units, and remote healthcare facilities.
In addition to its core hardware offering, Hyperfine provides an integrated software platform that enables secure image transmission, cloud-based storage and on-demand interpretation. This connectivity allows clinicians to consult with specialists in real time, accelerating diagnosis and treatment decisions for conditions such as stroke, traumatic brain injury and intracranial hemorrhage. The company also offers training, installation support and application development services to ensure seamless adoption across diverse clinical environments.
Founded in 2014 and headquartered in Guilford, Connecticut, Hyperfine was co-founded by a team of entrepreneurs and imaging experts seeking to transform the MRI market. The Swoop system received 510(k) clearance from the U.S. Food and Drug Administration in 2020, followed by CE mark authorization for distribution in Europe. Since then, the company has expanded its commercial footprint to include academic medical centers, community hospitals and mobile care units across North America, Europe and select international markets.
Under the leadership of President and Chief Executive Officer Todd Fruchterman, Hyperfine has forged strategic partnerships with healthcare providers, research institutions and non-profit organizations to validate its technology in clinical studies and real-world applications. The executive team, which brings together expertise in imaging science, regulatory affairs and global sales, continues to pursue innovation aimed at lowering the cost and complexity of diagnostic imaging while improving patient outcomes worldwide.
